Polaryx Trial Ignites Hope for Rare Childhood Neurological Diseases

PARAMUS, NJ – February 27, 2026 – As the world observes Rare Disease Day, a day dedicated to raising awareness for the more than 300 million people battling conditions few have heard of, Polaryx Therapeutics has offered a tangible beacon of hope. The clinical-stage biotechnology company reaffirmed its commitment to this underserved community by announcing the advancement of SOTERIA, a crucial Phase 2 clinical trial for its lead drug candidate, PLX-200.

This trial targets four distinct and devastating rare pediatric lysosomal storage disorders (LSDs): CLN2 and CLN3 diseases (forms of Batten disease), Krabbe disease, and Sandhoff disease. These genetic conditions are characterized by rapid, progressive neurodegeneration, robbing children of their motor skills, sight, and cognitive function, and ultimately, their lives. With limited or non-existent treatment options for many of these diseases, Polaryx’s efforts represent a significant step forward in a field defined by profound unmet medical need.

“On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments,” said Alex Yang, Chairman and Chief Executive Officer of Polaryx Therapeutics, in a statement. “We are deeply committed to raising awareness of rare pediatric lysosomal storage disorders and developing disease-modifying, family-friendly therapies.”

A Novel Strategy Against Cellular Sabotage

Lysosomal storage disorders are a group of over 50 inherited diseases caused by genetic defects that disrupt the function of lysosomes, the cell's critical waste-recycling centers. When lysosomes fail, toxic materials accumulate, leading to cellular dysfunction, chronic inflammation, and cell death, with the brain and nervous system being particularly vulnerable. This cellular sabotage manifests as the catastrophic symptoms seen in affected children.

Polaryx's lead candidate, PLX-200, is not a gene therapy designed to fix the root genetic mutation. Instead, it is an orally administered small molecule that takes a different approach: empowering the cell's own machinery to overcome the defect. PLX-200, a reformulated version of the long-approved drug gemfibrozil, is designed to activate key cellular regulators like transcription factor EB (TFEB) and PPARs. This activation boosts the production of functional lysosomes and enhances the clearance of toxic materials, while also reducing the damaging neuroinflammation that accelerates disease progression.

This strategy is built on a strong preclinical foundation. In animal models of Batten disease, PLX-200 prolonged lifespan, delayed the loss of mobility, and reduced the accumulation of waste materials in the brain. More recent data presented in February 2026 showed that in a mouse model of Krabbe disease, the treatment protected myelin—the protective sheath around nerves—restored motor function, and significantly increased lifespan. The drug's ability to cross the blood-brain barrier is a crucial advantage for treating these primarily neurological conditions.

By using a reformulated version of an existing drug, Polaryx is leveraging the FDA's 505(b)(2) regulatory pathway, which can potentially streamline development by relying on existing safety data, a strategy that could shorten the timeline to get a therapy to patients who have no time to wait.

Redefining the Playbook for Orphan Drug Development

The SOTERIA trial is as innovative as the science behind it. Polaryx has designed it as a Phase 2 “basket trial,” a modern and efficient approach where a single drug is tested across multiple diseases that share a common biological mechanism. Instead of running four separate, costly, and time-consuming trials, the basket design allows the company to evaluate PLX-200’s potential in CLN2, CLN3, Krabbe, and Sandhoff disease simultaneously under a single protocol.

This design is particularly well-suited for the challenges of rare disease research, where patient populations are small and geographically scattered. For the CLN2 and CLN3 cohorts, the trial will also incorporate natural history data as an external control arm. This avoids the ethical dilemma of assigning severely ill children to a placebo group when no other treatments exist, a forward-thinking approach increasingly supported by regulatory agencies like the FDA.

This strategic efficiency is vital in the competitive orphan drug market. While the global LSD treatment market is valued in the billions and growing, few effective therapies exist for the specific diseases Polaryx is targeting. BioMarin's Brineura is an approved enzyme replacement therapy for CLN2, but it requires invasive administration. For Krabbe and Sandhoff diseases, there is no established standard of care beyond supportive measures. Polaryx’s development of a patient-friendly oral drug that could potentially treat multiple disorders gives it a unique position. This strategic vision has not gone unnoticed, with financial analysts at Maxim recently initiating coverage with a “Buy” rating and a $10 price target, citing the company's strong financial position and differentiated approach.

The Human Cost and the Urgent Need for a Breakthrough

Behind the science and market strategy lies a devastating human reality. Juvenile Batten disease (CLN3) typically begins with vision loss in childhood and progresses to seizures, cognitive decline, and loss of motor function, with death often occurring in the late teens or early twenties. Krabbe disease, in its most common infantile form, is even more rapid, causing severe neurological decline and typically leading to death by age two. For families receiving these diagnoses, the journey is one of heartbreak and a desperate search for hope.

Patient advocacy groups like the Batten Disease Support and Research Association (BDSRA) and KrabbeConnect work tirelessly to support families and fund research, highlighting the immense gap between the diseases' severity and the available treatments. The SOTERIA trial, therefore, represents more than just a corporate milestone; for these communities, it is a critical and tangible step toward a potential future where a diagnosis is not an immediate death sentence.

Having received a “safe to proceed” letter from the FDA in October 2025, Polaryx is moving with urgency. The SOTERIA trial is slated to begin enrolling patients in the first half of 2026, with clinical sites planned not only in the United States but also in Europe and Asia, acknowledging the global impact of these rare conditions. Should the trial demonstrate compelling clinical activity, the company may be able to pursue conditional marketing authorization, potentially accelerating access to a therapy that families have been waiting for. For children facing a relentless ticking clock, that possibility is everything.